Abstract Number: 879 • 2019 ACR/ARP Annual Meeting
Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study
Background/Purpose: To evaluate use of marijuana (MJ) and cannabidiol (CBD) as described by rheumatology patients at an academic medical center in Vermont, and to describe beliefs and…Abstract Number: 2929 • 2019 ACR/ARP Annual Meeting
Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results…Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…Abstract Number: 7L • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
Background/Purpose: Effective treatment options are limited for refractory skin disease in dermatomyositis (DM). Anabasum is a non-immunosuppressive, synthetic, oral preferential CB2 agonist that triggers resolution…Abstract Number: 725 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001
Background/Purpose: Anabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models of…Abstract Number: 738 • 2017 ACR/ARHP Annual Meeting
Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Background/Purpose: Skin thickening is the defining manifestation of dcSSc. A dcSSc patient’s assessment of their skin involvement can provide information about how that patient feels…Abstract Number: 976 • 2017 ACR/ARHP Annual Meeting
Cannabinoid Receptor 2 Agonist (JWH-015) Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by activated synovial fibroblasts in which pro-inflammatory cytokine interleukin-1β (IL-1β) mediates inflammation. The endocannabinoid system…Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis. Anabasum is a non-immunosuppressive, synthetic, orally administered…Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study
Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting
Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis
Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…Abstract Number: 1029 • 2014 ACR/ARHP Annual Meeting
Anandamide and Related Eicosanoids Decrease the Production of Pro-Inflammatory Cytokines in Synovial Fibroblasts By a COX-2 Dependent Mechanism: Involvement of Calcium and TRP Channels
Background/Purpose: Endocannabinoids are immunomodulatory lipid compounds that act on cannabinoid receptors type 1 and 2 but also on transient receptor potential (TRP) channels. Their action…Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…Abstract Number: 122 • 2013 ACR/ARHP Annual Meeting
Rheumatologists Lack Confidence in Their Knowledge of Cannabinoid Molecules and Use in the Management of Rheumatic Disease Patients: Analysis of a Needs Assessment
Background/Purpose: The pharmacologic treatment of chronic rheumatic pain is often sub-optimal, leading patients to seek alternate treatments. Although herbal cannabis (marihuana) has had medicinal use…